Published in J Clin Microbiol on September 01, 2004
Identification of Burkholderia cepacia complex bacteria with a lipopolysaccharide-specific monoclonal antibody. J Med Microbiol (2010) 0.83
Phylogeographic, genomic, and meropenem susceptibility analysis of Burkholderia ubonensis. PLoS Negl Trop Dis (2017) 0.75
A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem (1982) 36.39
Lipopolysaccharide endotoxins. Annu Rev Biochem (2001) 18.88
Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun (1983) 6.24
Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol (1997) 5.60
DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III. J Clin Microbiol (2000) 4.71
Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol (2001) 4.02
Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol (2000) 3.77
The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med (1995) 3.36
Development of rRNA-based PCR assays for identification of Burkholderia cepacia complex isolates recovered from cystic fibrosis patients. J Clin Microbiol (1999) 3.19
Linkage analysis of geographic and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping. J Clin Microbiol (1994) 2.74
The relationship of phenotype changes in Pseudomonas aeruginosa to the clinical condition of patients with cystic fibrosis. Am Rev Respir Dis (1983) 2.68
Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med (2001) 2.55
Burkholderia cenocepacia sp. nov.--a new twist to an old story. Res Microbiol (2003) 2.49
Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr (2001) 2.31
Pseudomonas cepacia typing systems: collaborative study to assess their potential in epidemiologic investigations. Rev Infect Dis (1989) 2.25
Genetic variation at the O-antigen biosynthetic locus in Pseudomonas aeruginosa. J Bacteriol (2002) 2.13
Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. FEMS Immunol Med Microbiol (2002) 1.86
Comparative assessment of genotyping methods for epidemiologic study of Burkholderia cepacia genomovar III. J Clin Microbiol (2002) 1.79
Updated version of the Burkholderia cepacia complex experimental strain panel. J Clin Microbiol (2003) 1.74
Genomic organization of LPS-specific loci. Curr Top Microbiol Immunol (2002) 1.45
Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol Lett (2003) 1.38
Characterization of the serogroup O11 O-antigen locus of Pseudomonas aeruginosa PA103. J Bacteriol (1999) 1.33
Multilocus restriction typing: a novel tool for studying global epidemiology of Burkholderia cepacia complex infection in cystic fibrosis. J Infect Dis (2002) 1.31
Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom. J Clin Microbiol (2000) 1.24
O and H serotyping of Pseudomonas cepacia. J Clin Microbiol (1983) 1.24
Pseudomonas aeruginosa galU is required for a complete lipopolysaccharide core and repairs a secondary mutation in a PA103 (serogroup O11) wbpM mutant. FEMS Microbiol Lett (2002) 1.23
Burkholderia and emerging pathogens in cystic fibrosis. Semin Respir Crit Care Med (2003) 1.23
Lipopolysaccharide of Burkholderia cepacia complex. J Endotoxin Res (2003) 1.15
Population structure analysis of Burkholderia cepacia genomovar III: varying degrees of genetic recombination characterize major clonal complexes. Microbiology (2003) 1.12
Functional conservation of the polysaccharide biosynthetic protein WbpM and its homologues in Pseudomonas aeruginosa and other medically significant bacteria. Infect Immun (2000) 1.02
Lack of correlation between O-serotype, bacteriophage susceptibility and genomovar status in the Burkholderia cepacia complex. FEMS Immunol Med Microbiol (2003) 0.82
[Immunologic and structural studies of lipopolysaccharides from Pseudomonas cepacia]. Mikrobiol Zh (1989) 0.80
New serotypes of Pseudomonas cepacia. Res Microbiol (1989) 0.76
The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol (2005) 5.38
Parallel bacterial evolution within multiple patients identifies candidate pathogenicity genes. Nat Genet (2011) 4.81
Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosus gen. nov., sp. nov. J Clin Microbiol (2002) 3.44
Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A (2012) 3.43
Burkholderia xenovorans LB400 harbors a multi-replicon, 9.73-Mbp genome shaped for versatility. Proc Natl Acad Sci U S A (2006) 3.07
Regulation of virulence determinants in Staphylococcus aureus: complexity and applications. FEMS Microbiol Rev (2004) 3.01
Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells. J Biol Chem (2003) 2.72
Taxon K, a complex within the Burkholderia cepacia complex, comprises at least two novel species, Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov. Int J Syst Evol Microbiol (2009) 2.61
Burkholderia cenocepacia sp. nov.--a new twist to an old story. Res Microbiol (2003) 2.49
PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patients. J Clin Microbiol (2004) 2.31
Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J Clin Microbiol (2005) 2.18
Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann Am Thorac Soc (2013) 2.05
Infection by Ralstonia species in cystic fibrosis patients: identification of R. pickettii and R. mannitolilytica by polymerase chain reaction. Emerg Infect Dis (2002) 1.88
An epidemic Burkholderia cepacia complex strain identified in soil. Lancet (2002) 1.88
Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients. J Clin Microbiol (2002) 1.87
Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. FEMS Immunol Med Microbiol (2002) 1.86
Comparative assessment of genotyping methods for epidemiologic study of Burkholderia cepacia genomovar III. J Clin Microbiol (2002) 1.79
Updated version of the Burkholderia cepacia complex experimental strain panel. J Clin Microbiol (2003) 1.74
Species abundance and diversity of Burkholderia cepacia complex in the environment. Appl Environ Microbiol (2005) 1.62
Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. Int J Syst Evol Microbiol (2004) 1.58
Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5. Infect Immun (2005) 1.51
IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J Immunol (2008) 1.42
Bartonella bovis Bermond et al. sp. nov. and Bartonella capreoli sp. nov., isolated from European ruminants. Int J Syst Evol Microbiol (2002) 1.42
Impact of enhanced Staphylococcus DNA extraction on microbial community measures in cystic fibrosis sputum. PLoS One (2012) 1.40
Involvement of a plasmid-encoded type IV secretion system in the plant tissue watersoaking phenotype of Burkholderia cenocepacia. J Bacteriol (2004) 1.40
H. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression. FASEB J (2006) 1.40
Crystal structure of leucotoxin S component: new insight into the Staphylococcal beta-barrel pore-forming toxins. J Biol Chem (2004) 1.38
Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol Lett (2003) 1.38
Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med (2008) 1.37
Metabolic network analysis of Pseudomonas aeruginosa during chronic cystic fibrosis lung infection. J Bacteriol (2010) 1.37
Environmental Burkholderia cepacia complex isolates in human infections. Emerg Infect Dis (2007) 1.36
Pseudomonas aeruginosa increases formation of multidrug-tolerant persister cells in response to quorum-sensing signaling molecules. J Bacteriol (2010) 1.35
Sepsis, multiple organ failure, and death due to Pandoraea pnomenusa infection after lung transplantation. J Clin Microbiol (2003) 1.35
Use of the gyrB gene for the identification of Pandoraea species. FEMS Microbiol Lett (2002) 1.33
Proteolytic regulation of alginate overproduction in Pseudomonas aeruginosa. Mol Microbiol (2012) 1.31
Multilocus restriction typing: a novel tool for studying global epidemiology of Burkholderia cepacia complex infection in cystic fibrosis. J Infect Dis (2002) 1.31
Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis (2010) 1.29
Classification of Ralstonia pickettii-like isolates from the environment and clinical samples as Ralstonia insidiosa sp. nov. Int J Syst Evol Microbiol (2003) 1.28
Expanded multilocus sequence typing for burkholderia species. J Clin Microbiol (2009) 1.26
Using BOX-PCR to exclude a clonal outbreak of melioidosis. BMC Infect Dis (2007) 1.24
Isolations of Corynebacterium kroppenstedtii from a breast abscess. Int J Med Microbiol (2004) 1.24
Multilocus sequence typing breathes life into a microbial metagenome. PLoS One (2006) 1.23
Pseudomonas aeruginosa galU is required for a complete lipopolysaccharide core and repairs a secondary mutation in a PA103 (serogroup O11) wbpM mutant. FEMS Microbiol Lett (2002) 1.23
Use of PCR analyses to define the distribution of Ralstonia species recovered from patients with cystic fibrosis. J Clin Microbiol (2005) 1.23
Incidence and pathogenic effect of Streptococcus pseudopneumoniae. J Clin Microbiol (2006) 1.23
Contribution of Burkholderia cenocepacia flagella to infectivity and inflammation. Infect Immun (2004) 1.22
Burkholderia pseudomultivorans sp. nov., a novel Burkholderia cepacia complex species from human respiratory samples and the rhizosphere. Syst Appl Microbiol (2013) 1.21
Divergence and mosaicism among virulent soil phages of the Burkholderia cepacia complex. J Bacteriol (2006) 1.20
Reconstitution of O-specific lipopolysaccharide expression in Burkholderia cenocepacia strain J2315, which is associated with transmissible infections in patients with cystic fibrosis. J Bacteriol (2005) 1.20
Aeromonas simiae sp. nov., isolated from monkey faeces. Int J Syst Evol Microbiol (2004) 1.18
Mimicking helical antibacterial peptides with nonpeptidic folding oligomers. Chem Biol (2006) 1.18
The galU Gene of Pseudomonas aeruginosa is required for corneal infection and efficient systemic spread following pneumonia but not for infection confined to the lung. Infect Immun (2004) 1.18
Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc Natl Acad Sci U S A (2007) 1.17
Molecular epidemiology of Burkholderia species. Front Biosci (2003) 1.16
Risk factors for Burkholderia cepacia complex bacteremia among intensive care unit patients without cystic fibrosis: a case-control study. Infect Control Hosp Epidemiol (2007) 1.16
Ralstonia respiraculi sp. nov., isolated from the respiratory tract of cystic fibrosis patients. Int J Syst Evol Microbiol (2003) 1.15
Lipopolysaccharide of Burkholderia cepacia complex. J Endotoxin Res (2003) 1.15
Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. Future Oncol (2010) 1.14
Recurrent Burkholderia infection in patients with chronic granulomatous disease: 11-year experience at a large referral center. Clin Infect Dis (2009) 1.14
Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol (2014) 1.13
Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect Immun (2003) 1.13
mexEF-oprN multidrug efflux operon of Pseudomonas aeruginosa: regulation by the MexT activator in response to nitrosative stress and chloramphenicol. Antimicrob Agents Chemother (2010) 1.12
Population structure analysis of Burkholderia cepacia genomovar III: varying degrees of genetic recombination characterize major clonal complexes. Microbiology (2003) 1.12
Peptide deformylase as an antibacterial target: a critical assessment. Curr Opin Pharmacol (2006) 1.12
Culture-based and non-growth-dependent detection of the Burkholderia cepacia complex in soil environments. Appl Environ Microbiol (2002) 1.11
Control of the oxidative burst of human neutrophils by staphylococcal leukotoxins. Infect Immun (2003) 1.11
Nitrogen redox balance in the cystic fibrosis airway: effects of antipseudomonal therapy. Am J Respir Crit Care Med (2002) 1.09
Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei. Expert Rev Vaccines (2008) 1.09
Burkholderia cepacia complex in cystic fibrosis: frequency of strain replacement during chronic infection. Clin Infect Dis (2003) 1.08
Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine. Infect Immun (2002) 1.08
Novel phosphorylcholine-containing protein of Pseudomonas aeruginosa chronic infection isolates interacts with airway epithelial cells. J Infect Dis (2008) 1.08
Analysis of the Pseudomonas aeruginosa regulon controlled by the sensor kinase KinB and sigma factor RpoN. J Bacteriol (2011) 1.06
Six-year molecular analysis of Burkholderia cepacia complex isolates among cystic fibrosis patients at a referral center for lung transplantation. J Clin Microbiol (2002) 1.06
Classification of Achromobacter genogroups 2, 5, 7 and 14 as Achromobacter insuavis sp. nov., Achromobacter aegrifaciens sp. nov., Achromobacter anxifer sp. nov. and Achromobacter dolens sp. nov., respectively. Syst Appl Microbiol (2013) 1.05
Intracellular trafficking and replication of Burkholderia cenocepacia in human cystic fibrosis airway epithelial cells. Cell Microbiol (2006) 1.05
Elucidating global epidemiology of Burkholderia multivorans in cases of cystic fibrosis by multilocus sequence typing. J Clin Microbiol (2007) 1.04
Effect of sample storage conditions on culture-independent bacterial community measures in cystic fibrosis sputum specimens. J Clin Microbiol (2011) 1.03
Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect Immun (2004) 1.03
Helicobacter pylori induces interleukin-8 secretion by Toll-like receptor 2- and Toll-like receptor 5-dependent and -independent pathways. Infect Immun (2005) 1.03
Involvement of a quorum-sensing-regulated lipase secreted by a clinical isolate of Burkholderia glumae in severe disease symptoms in rice. Appl Environ Microbiol (2007) 1.02
Consequences of isostructural main-chain modifications for the design of antimicrobial foldamers: helical mimics of host-defense peptides based on a heterogeneous amide/urea backbone. Angew Chem Int Ed Engl (2010) 1.02
The structure of the lipopolysaccharide from a galU mutant of Pseudomonas aeruginosa serogroup-O11. Carbohydr Res (2005) 1.02
Toll-like receptor 2-mediated gene expression in epithelial cells during Helicobacter pylori infection. Helicobacter (2005) 1.01
Pseudomonas aeruginosa 1244 pilin glycosylation: glycan substrate recognition. J Bacteriol (2006) 1.01
Achromobacter animicus sp. nov., Achromobacter mucicolens sp. nov., Achromobacter pulmonis sp. nov. and Achromobacter spiritinus sp. nov., from human clinical samples. Syst Appl Microbiol (2012) 1.01
Overexpression of Mycobacterium tuberculosis manB, a phosphomannomutase that increases phosphatidylinositol mannoside biosynthesis in Mycobacterium smegmatis and mycobacterial association with human macrophages. Mol Microbiol (2005) 1.00
Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc (2014) 1.00
Construction of mobilizable mini-Tn7 vectors for bioluminescent detection of gram-negative bacteria and single-copy promoter lux reporter analysis. Appl Environ Microbiol (2013) 1.00
Construction of a broad-host-range Tn7-based vector for single-copy P(BAD)-controlled gene expression in gram-negative bacteria. Appl Environ Microbiol (2012) 1.00
Isolation of sulfate-reducing bacteria from human thoracoabdominal pus. J Clin Microbiol (2003) 0.99